[Design and application of oral sustained-release anticancer drug--a new oral dosage form of cisplatin]. 1998

T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
Department of Pharmaceutics and Pharmacokinetics, Kyoto Pharmaceutical University.

As compared to the conventional standard chemotherapy of solid cancer such as lung, biochemical modulation (BCM) therapy has been proven to have a good therapeutic efficiency. BCM therapy uses the low dose and low infusion rate of anti-cancer drug. To increase of the QOL of cancer patients, oral BCM therapy is needed. For this purpose, two kinds of new oral sustained-release cisplatin preparations were developed, micro-porous CDDP capsule made of ethylcellulose(EC) and CDDP-EC-stearic acid solid dispersion. After oral administrations of these preparations, serum CDDP levels were maintained over 0.2 microgram/ml for 24h. Experimental therapy using P815 tumor cells transplanted mice suggested the usefulness of CDDP solid dispersion preparation.

UI MeSH Term Description Entries
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D002214 Capsules Hard or soft soluble containers used for the oral administration of medicine. Capsule,Microcapsule,Microcapsules
D002482 Cellulose A polysaccharide with glucose units linked as in CELLOBIOSE. It is the chief constituent of plant fibers, cotton being the purest natural form of the substance. As a raw material, it forms the basis for many derivatives used in chromatography, ion exchange materials, explosives manufacturing, and pharmaceutical preparations. Alphacel,Avicel,Heweten,Polyanhydroglucuronic Acid,Rayophane,Sulfite Cellulose,alpha-Cellulose,Acid, Polyanhydroglucuronic,alpha Cellulose
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013229 Stearic Acids A group of compounds that are derivatives of octadecanoic acid which is one of the most abundant fatty acids found in animal lipids. (Stedman, 25th ed) Dihydrooleic Acids,Octadecanoic Acids,Tetrahydrolinoleic Acids,Acids, Dihydrooleic,Acids, Octadecanoic,Acids, Stearic,Acids, Tetrahydrolinoleic

Related Publications

T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
July 1963, Journal of pharmaceutical sciences,
T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
May 1989, Drug design and delivery,
T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
August 1959, Journal of the American Pharmaceutical Association. American Pharmaceutical Association,
T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
January 1994, Journal of microencapsulation,
T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
March 2004, British journal of clinical pharmacology,
T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
January 2015, International journal of pharmaceutical investigation,
T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
January 2008, AAPS PharmSciTech,
T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
January 2020, Current drug research reviews,
T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
October 1975, Journal of pharmaceutical sciences,
T Nakagawa, and T Kawamura, and Y Matsumura, and Y Yoshikawa, and K Takada, and O Ike, and H Wada, and S Hitomi
May 1996, The Journal of pharmacy and pharmacology,
Copied contents to your clipboard!